| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/26/2023 | 30.89% | Stephens & Co. | → $10 | Reiterates | Equal-Weight → Equal-Weight |
| 08/15/2023 | 57.07% | Raymond James | → $12 | Upgrades | Market Perform → Outperform |
| 08/09/2023 | — | HC Wainwright & Co. | Reiterates | → Neutral | |
| 07/11/2023 | — | Raymond James | Maintains | Market Perform | |
| 05/11/2023 | — | BTIG | Downgrades | Buy → Neutral | |
| 03/07/2023 | 17.8% | Stephens & Co. | $19 → $9 | Downgrades | Overweight → Equal-Weight |
| 03/07/2023 | 70.16% | Goldman Sachs | $25 → $13 | Maintains | Buy |
| 03/03/2023 | 17.8% | Craig-Hallum | $26 → $9 | Downgrades | Buy → Hold |
| 03/03/2023 | 214.14% | Raymond James | → $24 | Downgrades | Strong Buy → Market Perform |
| 02/28/2023 | 227.23% | BTIG | $28 → $25 | Maintains | Buy |
| 02/28/2023 | 148.69% | Stephens & Co. | → $19 | Reiterates | → Overweight |
| 02/28/2023 | 240.31% | Craig-Hallum | $32 → $26 | Maintains | Buy |
| 02/28/2023 | 227.23% | Goldman Sachs | $29 → $25 | Maintains | Buy |
| 02/16/2023 | 148.69% | Stephens & Co. | → $19 | Reiterates | → Overweight |
| 02/06/2023 | 279.58% | Goldman Sachs | $40 → $29 | Maintains | Buy |
| 01/31/2023 | 214.14% | Raymond James | $26 → $24 | Maintains | Strong Buy |
| 11/08/2022 | 240.31% | Raymond James | $35 → $26 | Maintains | Strong Buy |
| 11/07/2022 | 266.49% | BTIG | $37 → $28 | Maintains | Buy |
| 11/04/2022 | 423.56% | Goldman Sachs | $45 → $40 | Maintains | Buy |
| 08/10/2022 | 358.12% | Raymond James | $45 → $35 | Maintains | Strong Buy |
| 05/06/2022 | 489.01% | Raymond James | $52 → $45 | Maintains | Strong Buy |
| 04/25/2022 | 554.45% | Stephens & Co. | → $50 | Initiates Coverage On | → Overweight |
| 02/25/2022 | 580.63% | Raymond James | $90 → $52 | Maintains | Strong Buy |
| 10/29/2021 | 1078.01% | Raymond James | $108 → $90 | Maintains | Strong Buy |
| 06/28/2021 | 1313.61% | Raymond James | $90 → $108 | Maintains | Strong Buy |
| 06/03/2021 | 1143.46% | Goldman Sachs | → $95 | Initiates Coverage On | → Buy |
| 05/06/2021 | 1078.01% | Raymond James | $98 → $90 | Maintains | Strong Buy |
| 02/25/2021 | 1182.72% | Raymond James | $101 → $98 | Maintains | Strong Buy |
| 12/10/2020 | 881.68% | Raymond James | $62 → $75 | Maintains | Strong Buy |
| 10/30/2020 | 711.52% | Raymond James | $42 → $62 | Maintains | Strong Buy |
| 10/30/2020 | 619.9% | HC Wainwright & Co. | $47 → $55 | Maintains | Buy |
| 10/08/2020 | 515.18% | HC Wainwright & Co. | $45 → $47 | Maintains | Buy |
| 10/02/2020 | 489.01% | HC Wainwright & Co. | $40 → $45 | Maintains | Buy |
| 08/05/2020 | 449.74% | Raymond James | $40 → $42 | Maintains | Strong Buy |
| 08/05/2020 | 423.56% | HC Wainwright & Co. | $37 → $40 | Maintains | Buy |
| 06/26/2020 | 423.56% | BTIG | → $40 | Initiates Coverage On | → Buy |
| 06/19/2020 | 384.29% | HC Wainwright & Co. | $40 → $37 | Maintains | Buy |
| 05/01/2020 | 423.56% | HC Wainwright & Co. | $43 → $40 | Reiterates | → Buy |
| 10/01/2019 | 528.27% | Craig-Hallum | → $48 | Initiates Coverage On | → Buy |
| 08/02/2019 | 528.27% | Raymond James | $46 → $48 | Maintains | Strong Buy |
| 05/09/2019 | 462.83% | HC Wainwright & Co. | $30 → $43 | Upgrades | Neutral → Buy |
| 03/22/2019 | 502.09% | Raymond James | $38 → $46 | Maintains | Strong Buy |
| 02/15/2019 | 358.12% | Jefferies | → $35 | Initiates Coverage On | → Buy |
What is the target price for CareDx (CDNA)?
The latest price target for CareDx (NASDAQ: CDNA) was reported by Stephens & Co. on September 26, 2023. The analyst firm set a price target for $10.00 expecting CDNA to rise to within 12 months (a possible 30.89% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CareDx (CDNA)?
The latest analyst rating for CareDx (NASDAQ: CDNA) was provided by Stephens & Co., and CareDx reiterated their equal-weight rating.
When is the next analyst rating going to be posted or updated for CareDx (CDNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CareDx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CareDx was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.
Is the Analyst Rating CareDx (CDNA) correct?
While ratings are subjective and will change, the latest CareDx (CDNA) rating was a reiterated with a price target of $0.00 to $10.00. The current price CareDx (CDNA) is trading at is $7.64, which is within the analyst's predicted range.